These findings further confirm the involvement of JAK3 in the development of resistance to EGFR-TKIs in EGFR-sensitive mutant lung adenocarcinoma, thereby offering a novel therapeutic strategy for addressing EGFR-TKI resistance. Here, JAK3 is linked to lung adenocarcinoma.